Heather Losey, PhD of Alkermes discusses ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Read here: https://jitc.bmj.com/content/8/1/e000673
Advertisement
Heather Losey, PhD on ALKS 4230
